Tosk Communications

Tosk is a clinical-stage biopharmaceutical company focused on developing drugs that improve the outcomes of cancer treatment by preventing the adverse side effects of existing therapies. The company's proprietary Side Effect Filter (SEF) technology platform identifies small molecule "companion" drugs that selectively block the toxicity of widely used chemotherapeutic agents without reducing their anti-tumor efficacy. Tosk's lead candidate, TK-90, is designed to prevent mucositis caused by methotrexate and 5-fluorouracil, while other programs target cardiotoxicity and nephrotoxicity. Additionally, the company is leveraging its discovery platform to develop direct-acting inhibitors for difficult-to-treat targets like the Ras oncogene. By mitigating treatment-limiting toxicities, Tosk aims to enable more effective dosing regimens and improve patient quality of life.